Listar por autor "Escudero, E."

Ordenar por:Orden:Resultados:

  • Acetazolamide and N-acetylcysteine in the treatment of chronic mountain sickness (Monge's disease) 
    Sharma, S.; Gralla, J.; Ordonez, J. G.; Hurtado, M. E.; Swenson, E. R.; Schoene, R. B.; Kelly, J. P.; Callacondo, D.; Rivard, C.; Roncal-Jimenez, C.; Sirota, J.; Fuquay, R.; Jackson, B. P.; Swenson, K. E.; Johnson, R. J.; Hurtado, A.; Escudero, E. (Elsevier, 2017)
    Patients suffering from chronic mountain sickness (CMS) have excessive erythrocytosis. Low level cobalt toxicity as a likely contributor has been demonstrated in some subjects. We performed a randomized, placebo controlled ...
  • Cardiovascular and renal effects of chronic exposure to high altitude 
    Hurtado, A.; Escudero, E.; Pando, J.; Sharma, S.; Johnson, R.J. (Oxford University Press, 2012)
    Over 140 million people live at high altitude, defined as living at an altitude of 2400 m or more above sea level. Subjects living under these conditions are continuously living under hypoxic conditions and, depending on ...
  • The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics 
    Wheeler, D.C.; Stefansson, B.V.; Batiushin, M.; Bilchenko, O.; Cherney, D.Z.I.; Chertow, G.M.; Douthat, W.; Dwyer, J.P.; Escudero, E.; Pecoits-Filho, R.; Furuland, H.; Górriz, J.L.; Greene, T.; Haller, H.; Hou, F.F.; Kang, S.-W.; Isidto, R.; Khullar, D.; Mark, P.B.; McMurray, J.J.V.; Kashihara, N.; Nowicki, M.; Persson, F.; Correa-Rotter, R.; Rossing, P.; Toto, R.D.; Umanath, K.; Van Bui, P.; Wittmann, I.; Lindberg, M.; Sjöström, C.D.; Langkilde, A.M.; Heerspink, H.J.L. (Oxford University Press, 2020)
    BACKGROUND: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin ...
  • Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions 
    Vart, P.; Correa-Rotter, R.; Hou, F.F.; Jongs, N.; Chertow, G.M.; Langkilde, A.M.; McMurray, J.J.V.; Rossing, P.; Sjöström, C.D.; Stefansson, B.V.; Toto, R.D.; Douthat, W.; Escudero, E.; Isidto, R.; Khullar, D.; Bajaj, H.S.; Wheeler, D.C.; Heerspink, H.J.L. (Elsevier, 2022)
    Introduction: This study aimed to examine the efficacy and safety of dapagliflozin in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial (NCT03036150) by geographic region. ...
  • High altitude renal syndrome (HARS) 
    Hurtado Arestegui, A.; Fuquay, R.; Sirota, J.; Swenson, E.R.; Schoene, R.B.; Jefferson, J.A.; Chen, W.; Yu, X.-Q.; Kelly, J.P.; Johnson, R.J.; Escudero, E. (American Society of Nephrolog, 2011)
    More than 140 million people live permanently at high altitude (>2400 m) under hypoxic conditions that challenge basic physiology. Here we present a short historical review of the populating of these regions and of evidence ...

Buscar en el Repositorio

Listar

Panel de Control